Description
HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
Product information
CAS Number: 1638851-44-1
Molecular Weight: 436.88
Formula: C22H25ClO7
Chemical Name: (1S,2S,3R,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-methoxy-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
Smiles: CO[C@@]12CO[C@@](O1)([C@H](O)[C@@H](O)[C@@H]2O)C1=CC(CC2C=CC(=CC=2)OCC)=C(Cl)C=C1
InChiKey: UFWQAQJFRMQRFR-CUUWFGFTSA-N
InChi: InChI=1S/C22H25ClO7/c1-3-28-16-7-4-13(5-8-16)10-14-11-15(6-9-17(14)23)22-20(26)18(24)19(25)21(27-2,30-22)12-29-22/h4-9,11,18-20,24-26H,3,10,12H2,1-2H3/t18-,19-,20+,21-,22-/m0/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
HSK0935 (Compound 31) demonstrates excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of 843-fold.
In Vivo:
HSK0935 treatment (1, 3, and 10 mg/kg) shows robust urinary glucose excretion in Sprague−Dawley (SD) rats and affects more urinary glucose excretion in Rhesus monkeys.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.